Introduction and Objective
The decision to provide adjuvant therapy to men with high risk pathologic features following radical prostatectomy (RP) is confounded by tremendous uncertainty. We prospectively evaluated the impact of the genomic classifier (GC) test (GenomeDx Biosciences Inc., Vancouver), which predicts metastasis risk after RP, on urologists' decision-making for adjuvant treatment of highrisk prostate cancer (PCa) patients. Subjects and Methods 150 adjuvant patients were enrolled into the study by 43 urologists from 19 community and academic practices. Patients with pathologic T3 stage classification (pT3) or positive surgical margin (SM+) after RP were included. For each patient, participating physicians were asked to provide a management recommendation prior to processing the GC test and again upon receiving the test results. Patients complete validated surveys on decisional quality and PCa-related anxiety and are followed for one year. In this interim analysis, we evaluated the pre-and post-GC visits.
Results
GC results were available for 141 patients. Median patient age at RP was 64 years; 66% and 51% of patients had pT3 and SM+ pathology, respectively. The median 5-year predicted probability of metastasis by the GC test was 5.0% (interquartile range [IQR] 2.2%-10.7%). GC classified 48%,
20% and 32% of men as low-, intermediate-and high-risk, respectively. Without GC, observation was recommended for 88% (n=124), and 12% (n=17) received a recommendation for adjuvant radiation therapy (ART). Overall, 18% (95% confidence interval [CI] 12-26%) of adjuvant treatment recommendations changed post-GC, including 9% of low-risk GC patients, and 31% of high-risk GC patients. Decisional Conflict Scale (DCS) scores decreased (indicating higher decision quality)
after exposure to GC test results. Median DCS pre-GC was 25 (IQR 10-44) compared to 20 post-GC (p<0.001). GC results were associated with the decision to pursue ART, adjusting for clinical and pathologic parameters in multivariable logistic regression (odds ratio 1.47; 95% CI 1.18-1.83; p<0.001).
Conclusions
Observation is the predominantly prescribed management strategy among PCa patients with high risk features at RP. Knowledge of GC test results was associated with treatment decision-making among these patients: patients found to be low risk for metastasis by GC had higher rates of observation recommendations and patients at high risk had higher rates of ART recommendations. Decision quality was improved for patients when exposed to GC test results.
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